In 102 Australian adults aged 18–30, a genetically inactivated 2-component acellular pertussis vaccine (aP2) was non-inferior to Tdap3 for day-28 PT-IgG seroconversion (98.5% vs 82.4%) and FHA-IgG (87.7% vs 61.8%), with comparable safety.
RCTn = 102
Ong et al. Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: a randomized, controlled, non-inferiority trial